Drug
Pyruvate
Pyruvate is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph early_phase_1
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)
Trials by Status
completed267%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
completednot_applicable
Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)
NCT03797469
terminatedearly_phase_1
MRI With C13 Pilot Study Prostate Cancer
NCT02450201
completedphase_2
Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation
NCT00604331
Clinical Trials (3)
Showing 3 of 3 trials
NCT03797469Not Applicable
Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin)
NCT02450201Early Phase 1
MRI With C13 Pilot Study Prostate Cancer
NCT00604331Phase 2
Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3